The case for & against
Bull & Bear analysis
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) is a biopharmaceutical company focused on developing innovative peptide-based therapeutics for serious medical conditions, particularly rare blood disorders and inflammatory bowel diseases. The company is attempting to establish itself in the healthcare landscape through its proprietary technology platform aimed at developing new chemical entities (NCEs), such as Respartide for polycythemia vera and PN943 for inflammatory bowel disease. Protagonist is well-positioned in a niche market with significant unmet medical needs and competitive opportunity to capture market share through targeted therapies.
Bull says
- ↑14,300% YoY revenue growth to $28.6 M in 2020 driven by Janssen collaboration
- ↑Ends 2020 with $307.8 M cash, funding operations through mid-2024
- ↑Advancing five NCEs across six clinical studies, including Respartide pivotal trials
- ↑Respartide granted orphan drug and fast-track status, expediting FDA review
- ↑High momentum factors and 64% positive factor score indicate strong investor interest
- ↑Targets unmet IBD and blood disorder markets with peptide-based therapies
Bear says
- ↓Reported $66.2 M net loss in 2020 with $1.92 loss per share
- ↓R&D spend of $74.5 M heightens cash burn and profitability concerns
- ↓Elevated leverage risk and weak profitability factors may deter investors
- ↓Dependency on Janssen collaboration exposes revenue streams to partner risks
- ↓FDA and EMA approval delays for Respartide could postpone commercialization
- ↓Low patient adherence and market acceptance uncertainties may limit uptake
Investment themes with PTGX
Genetic and drug innovations driving medical breakthroughs
Earnings Call · Q4 2020 · Mgmt. Guidance
Transcript signals
Bull points
- we reported license and collaboration revenue for the full year of 2020 of $28.6 million as compared to $0.2 million for the full year of 2019.
- License and collaboration revenue for the fourth quarter of 2020 was $5.7 million compared to $2.7 million for the same period of 2019.
- We forecast the company's cash, cash equivalents, and marketable securities, along with access to our debt facility, will fund our planned operating and capital expenditures through mid-2024, allowing us to complete the current ongoing trials as well as fund our key clinical, regulatory, and operational activities through mid-2024.
Bear points
- this could be a drug of choice when the current therapy is ineffective. basically shows that majority of patients will fall in this category.
- In summary, we reported a net loss of $66.2 million or a net loss of $1.92 per share for the year end of 2020 compared to $77.2 million net loss or a net loss of $2.98 per share for the year end of 2019.
- for the fourth quarter of 2020, we reported a net loss of $18.9 million or a net loss of $0.48 per share compared to a net loss of $17.5 million or a net loss of $0.63 per share for the fourth quarter of 2019.